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httpcense.Abstract A sensitive, selective, precise and accurate stability-indicating high-performance thin
layer chromatographic method for analysis of Ivabradine hydrochloride (IH) an anti anginal agent,
both as a bulk drug and in formulations was developed and validated according to ICH guideline.
Densitometric analysis of IH was carried out in the absorbance mode at 287 nm using ethyl acetate:
0.389 M ammonium acetate in methanol (1:5, v/v) as solvent system. This system was found to give
compact spots for IH at an Rf value of 0.36 ± 0.01. Moreover, IH was subjected to acid and alkali
hydrolysis, oxidation, accelerated humidity/temperature, wet heat treatment, and photo degrada-
tion. The drug undergoes degradation under mainly acidic and basic conditions. Also the degraded
products were well resolved from the pure drug with signiﬁcantly different Rf values. Linearity was
found to be in the range of 1200–2800 ng/band. The LOD and LOQ for IH were 255.86 ng/band
and 775.33 ng/band, respectively. ‘‘Bartlett’s test’’ and ‘‘Lack of ﬁt’’ applied on peak area for line-
arity, additionally proved validity of the developed method. Good accuracy and precision were
obtained as revealed from %RSD value less than 2. Similarly, no interference was observed from
common excipients in tablet formulation as well as degradation product, indicating speciﬁcity of
the method. As the method could effectively separate the drug from its degradation product, it92250020.
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Figure 1 Chemical structure of I
234 M.H. Motisariya et al.can be employed as a stability-indicating one. Moreover, proposed method was also utilized to
investigate the kinetics of acidic degradation process at different temperatures and ﬁrst order rate
constant, half-life, shelf-life and activation energy were calculated.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
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Ivabradine hydrochloride (IH), chemically 3-[3-({[(7S)-3,
4dimethoxybicyclo[4.2.0]octa 1,3,5-trien-7yl]methyl}(methyl)ami-
no) propyl]-7,8dimethoxy-2,3,4,5-tetrahydro-1H-3 benzazepin-2-
one (Fig. 1), is an anti-ischaemic agent with speciﬁc negative
chronotropic action.1 IH is a speciﬁc heart rate lowering agent,
acting by reducing the rate of pacemaker activity in the sinoa-
trial node. Within the sinoatrial node, IH is a selective inhibi-
tor of If, an important current involved in generating the early
phase of spontaneous diastolic depolarization in pacemaker
cells, thereby reducing the frequency of action potential initia-
tion and lowering the heart rate.2 IH thereby prolongs the
duration of diastole, so as to improve the balance between
myocardial oxygen supply and demand as well as coronary
perfusion.3 In context to this, IH decreases oxygen consump-
tion thereby preventing symptoms and reducing morbidity
and mortality in patients with coronary artery disease and
angina.4
Literature reports, analysis of IH inhumanplasmaandurine,
rat anddog plasmabyhigh performance liquid chromatography
with ﬂuorescence detection and liquid chromatography–mass
spectrometrymethod.5,6Moreover, determination of IH inmar-
keted formulation by simpleHPLCandUV spectrophotometric
methods,dissolutionproﬁlestudyofimmediatereleasetabletfor-
mulationof IHbyHPLCarealsoavailable in literature.7–10Also,
stabilityindicatingHPLCmethodhasbeenreportedforthedeter-
minationofIHinbulkanddosageform.10Literaturereviewedre-
veals no information related to the stability-indicating
methodology by high performance thin layer chromatography
(HPTLC) for the determination of IH in pharmaceutical dosage
forms. Accordingly, the purpose of the present study is to put
ICHrecommendations intopracticeby subjecting IHtoavariety
ofsuggestedstresstestconditionsalongwithkineticstudytoestab-
lish inherent stabilityof thedrugandtodevelop thevalidated sta-
bility indicatingHPTLCassay.
According to the International Conference on Harmoni-
zation (ICH) guidelines, requirements for establishing SIMs
have become more clearly mandatory.11 Moreover, kinetic
studies and accelerated stability experiments play a signiﬁ-
cant role for solving problems encountered in quality control
and to predict the expiry dates of pharmaceutical products.
The purpose of stability testing is to provide evidence on
how the quality of a drug substance or drug product variesvabradine hydrochloride.with time under the inﬂuence of a variety of environmental
factors, such as temperature, light, oxygen, pH and mois-
ture. Stress testing can help in identifying degradation prod-
ucts and provide important information about the intrinsic
stability of drug substances.12
Although LC procedures are accurate and effective means
for analysis, they are time consuming; in addition, one of
the major drawbacks is the use of large amounts of solvents
and expensive instrumentation. As a consequence, rapid,
efﬁcient, and inexpensive analytical procedures that meet
the continuous need for high-throughput assays of the drugs
in quality control laboratories are highly demandable. Intro-
ducing TLC into pharmaceutical analysis represents a major
step in terms of quality assurance. Today, TLC and HPTLC
are rapidly becoming routine analytical techniques due to
their several advantages over other methods.13 The major
advantage of HPTLC is that several samples can be run
simultaneously using a small quantity of mobile phase unlike
HPLC, thus lowering the analysis time, sample clean up and
cost per analysis.14 Also, HPTLC plates are pre-coated with
smaller size particles, have narrow particle size distribution,
and possess smooth surfaces and thinner layers. Other char-
acteristics of HPTLC compared with TLC include smaller
sample volume, economy, faster separation, more reproduc-
ible results and lower detection limits. Furthermore, it pro-
vides processing of samples and standards at the same
time and so could be used for the quantitative determination
of such chemical compounds with high degree of accuracy
and precision. Thus, separation and quantiﬁcation can pro-
vide results that are either superior or comparable with
other analytical methods such as HPLC.15
An ideal stability indicating method hence was developed
by HPTLC that is capable of quantifying IH and can also
resolve IH from its degradation products. Furthermore, the
proposed method was used to study the degradation kinetics
proﬁle of IH under acidic condition at different temperature
and degradation kinetic parameters like activation energy,
degradation rate constant, t90 (where 90% of original con-
centration of drug is left) and t50 (half-life) were computed
from Arrhenius plot. The proposed stability indicating meth-
od is simple and allows rapid analysis for stability studies
and quality control analysis of drug in bulk and dosage
form.2. Experimental
2.1. Materials
Pharmaceutical grade of Ivabradine hydrochloride (IH) was
kindly supplied as a gift sample by Biocon Ltd., Andhra
Pradesh, India, used without further puriﬁcation. All sol-
vents and chemicals used were of analytical grade, pur-
chased from Merck Specialities Pvt. Ltd., India. Marketed
tablet dosage forms used in this study were IVABRAD5
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Healthcare Pvt. Ltd.) procured from local market.
2.2. Instrumentation
Microsyringe (Linomat syringe 659.0014, Hamilton-Bonaduz
Schweiz, Camag, Switzerland), pre-coated silica gel 60F254 alu-
minium plates (10 · 10 cm, 100 lm thickness; Merck, Darms-
tadt, Germany), Linomat 5 applicator (Camag, Switzerland),
twin trough chamber (10 · 20 cm; Camag, Switzerland), UV
chamber (Camag, Switzerland), TLC scanner IV (Camag,
Switzerland), winCATS version 1.4.6 software (Camag, Swit-
zerland) were used in the study.
2.3. Preparation of standard stock solution
A stock solution of IH was prepared by weighing accurately
10 mg of drug followed by dissolution and dilution in distilled
water to obtain a concentration of 100 lg/ml. This stock solu-
tion was appropriately diluted to make working standard solu-
tion as and when necessary.
2.4. Chromatographic procedure
The standard solutions of different concentrations were spot-
ted in the form of bands having a band width of 6 mm with
a microsyringe on pre-coated silica gel aluminium Plate
60F254, using a Camag Linomat 5sample applicator. Linear
ascending development was carried out in a twin trough glass
chamber. The mobile phase consisted of ethyl acetate: 0.389 M
ammonium acetate in methanol (1:5, v/v). The optimized
chamber saturation time before chromatographic development
was 20 min at room temperature (25 C± 2). The length of
chromatographic run was 8 cm which took an average of
12 min to develop. Subsequent to the development; HPTLC
plates were dried in a current of air with the help of an air
dryer. Densitometric scanning was performed using a Camag
TLC scanner IV with winCATS software. All measurements
were made in the reﬂectance–absorbance mode at 287 nm, slit
dimension (6.00 · 0.30 mm, micro), scanning speed 20 mm/s,
data resolution 100 lm/step. The source of radiation was deu-
terium lamp emitting a continuous UV spectrum between 190
and 400 nm. Concentration of the drug was determined from
the intensities of diffusely reﬂected lights. Evaluation was via
peak areas with linear regression analysis.
2.5. Calibration curve
Different volumes of the above standard solution were applied
and linear relationship between peak area and concentration of
the drugs was evaluated over the concentration range of 1200–
2800 ng/band by making ﬁve replicate measurements.
2.6. Method validation
The method was validated in accordance with ICH guidelines
Q2 (R1) for evaluation of linearity, precision, accuracy, LOD,
LOQ, speciﬁcity and robustness.16
2.6.1. Precision
Precision of the developed method was evaluated by per-
forming repeatability on same day and intermediate precisionstudies on different days and peak area measured was ex-
pressed in terms of percent relative standard deviation
(%RSD). Repeatability of sample application and
measurement of peak area were determined by six replicate
applications of same spot (1600 ng/band). Repeatability
and intermediate precision were carried out by performing
three replicates of three different concentrations (1200,
2000 and 2800 ng/band).
2.6.2. Accuracy
Accuracy of the method was ascertained by performing recov-
ery at three levels (80%, 100% and 120%), by spiking with IH
standard (960, 1200 and 1440 ng/band) to the dosage form
(1200 ng/band) by standard addition method. Recovery stud-
ies were performed in triplicate.
2.6.3. Limit of detection (LOD) and limit of quantitation
(LOQ)
As per ICH guideline, limit of detection and quantiﬁcation of
the developed method were calculated from the standard devi-
ation of the y-intercept and slope of the calibration curve of IH
using the formula,
Limit of detection ¼ 3:3  r=S ð1Þ
Limit of quantitation ¼ 10  r=S ð2Þ
where, ‘‘r’’ is standard deviation of response‘‘S’’ is slope of
calibration curve
2.6.4. Robustness
The effect of deliberate variations in method parameters like
the composition of the mobile phase ethyl acetate: 0.389 M
ammonium acetate in methanol (0.8:5.2, v/v) and (1.2:4.8, v/
v), saturation time (15 and 25 min), development distance (7
and 9 cm), spot scanning time interval (developed plate was
scanned after 1, 2, 3, 4, 5, and 6 h),wavelength scan (285 and
289 nm), time from spotting to chromatography (0, 20, 40
and 60 min), mobile phase volume (6, 12 and 18 ml) was eval-
uated. The effect of these changes on both the Rf values and
peak areas was evaluated by calculating the (%RSD) for each
parameter.
2.6.5. Speciﬁcity
The speciﬁcity of the method was ascertained by comparing
the samples of tablet formulation with standard drug. The
band for IH in sample was conﬁrmed by comparing the Rf val-
ues and peak purity spectra with that of standard. The peak
purity of IH was assessed by comparing the spectra at three
different levels, i.e., peak start (S), peak apex (M) and peak
end (E) position of the band. The speciﬁcity of the method
was also conﬁrmed by performing forced degradation studies
followed by comparison of Rf value and peak purity spectra
with that of standard.
2.7. Analysis of tablet dosage form
To determine the concentration of IH in tablet dosage form
(label claim: 5 and 7.5 mg per tablet), the contents of 20
tablet were accurately weighed, their mean weight was deter-
mined and ﬁnely powdered in a glass mortar. An accurately
weighed powder, equivalent to 10 mg of IH was weighed and
transferred into a 100 ml volumetric ﬂask containing 50 ml
236 M.H. Motisariya et al.distilled water, followed by sonication for 30 min and further
dilution up to mark with distilled water. The resulting solu-
tion was ﬁltered through whatman ﬁlter paper No. 42.
Twelve microlitres of the ﬁltered solution (1200 ng/band)
was applied on the TLC plate followed by development
and scanning as described in Section 2.2. The analysis was
repeated in triplicate.
2.8. Forced degradation studies
To evaluate the stability indicating property of the devel-
oped HPTLC method, IH was subjected to forced degrada-
tion conditions according to following procedures like acid/
base hydrolysis, oxidation, wet heat, temperature/humidity,
dry heat and photo-degradation followed by development
and scanning under optimized chromatographic conditions.
The forced degradation in acid, base and hydrogen peroxide
was performed in the dark, in order to exclude the possible
degradative effect of light on the drugs.17–21
(a) 1000 lg/ml solution of IH was reﬂuxed at 70 C for
45 min in different conditions: acid hydrolysis (0.1 and
1 M hydrochloric acid separately), base hydrolysis (0.1
and 1 M sodium hydroxide separately), oxidation
(0.3% and 3% hydrogen peroxide separately) and wet
heat degradation were done.
(b) 10 mg of IH powder was subjected to various condi-
tions: dry heat degradation (in an oven at 70 C for
24 h), photo-degradation (exposed to UV light in UV
chamber and sunlight for 24 h) and effect of tempera-
ture-humidity (in stability chamber at 40 C and 75%
RH for 24 h).2.9. Degradation kinetic investigation
To study the acid induced degradation kinetics of IH, ﬁnal
concentration of IH standard solution was 2 mg/ml in 1 M
hydrochloric acid. This ﬂask was reﬂuxed at 70, 80, 90 and
100 C temperatures. At speciﬁed time intervals, the content
of the ﬂask was quantitatively transferred to 25 ml volumetric
ﬂask and further neutralized to give a ﬁnal concentration of
1 mg/ml. From this neutralized solution, 2 ll (2000 ng/band)
was applied on HPTLC plate and development was carried
out under optimized chromatographic conditions. Each
experiment was repeated three times at each temperature
and time interval and the concentration of the IH remaining
after degradation was calculated. Further calculations were
done to obtain degradation rate constant, half-life, shelf-life
and activation energy from Arrhenius plot. Furthermore,
in situ UV densitometric scanning of both IH and degrada-
tion product was performed on HPTLC plates. Moreover,
DP was also separated by scrapping from the HPTLC plate
and IR spectra and Mass spectra of both IH and DP were
obtained.
2.10. Statistical analysis
Statistical parameters like SD, %RSD were computed by
using MS Excel. Bartlett’s test and test for Lack of ﬁt were
applied on the data of areas of linearity for evaluation of
homoscedasticity of variance and deviation from linearity.223. Results and discussion
3.1. Development of optimum mobile phase
In order to develop stability indicating method, pure drug and
its degraded product were applied on plates and different
solvents, alone and its combinations were tried in different ra-
tios. IH is a salt form, hence preliminary study was initiated
with different polar solvents with differing ratios (methanol:
water; 1:1, v/v) but retention factor was found to be less with
asymmetric peak shape. Acetic acid was hence added to in-
crease peak symmetry and Rf but, IH was unstable in acetic
acid. Hence, various other solvents were tried like methanol:
ethyl acetate: ammonia that gave high Rf value with very
broad and diffused peak. Toluene was added to above mobile
phase to decrease the Rf value but spot lacks compactness and
was less persistent. Alternatively, ammonia when replaced with
different concentrations of ammonium acetate salt was found
to separate both IH and its degradation product with an opti-
mum Rf value and very sharp narrow peak. The mobile phase
ﬁnally optimized for study was 0.3896 M ammonium acetate in
methanol:ethyl acetate in ratio of 5:1, v/v; resulting in Rf value
of 0.36 and 0.18 for IH and its degradation product, respec-
tively (as shown in Fig. 4). Sharp and well deﬁned symmetrical
peaks were obtained when the chamber was saturated with
mobile phase for 20 min at room temperature and scanned
at 287 nm on HPTLC plates.
3.2. Calibration curve
IH showed good correlation over a concentration range of
1200–2800 ng/spot with respect to peak area. The linearity of
calibration curve and adherence of system to Beer’s law were
evaluated by high value of correlation coefﬁcient. Further lin-
earity was validated by applying ‘‘Bartlett’s test’’ conﬁrming
homoscedasticity of variance that was exempliﬁed by v2 value
less than the tabulated value. Moreover, linearity was also
evaluated by ‘‘Lack of ﬁt’’ where deviation of peak area in
terms of F ratio was less than the tabulated one (Table 1).
3.3. Validation of method
3.3.1. Precision
%Relative standard deviation for repeatability of sample
application and measurement of peak area was found to be
0.88% and 0.96%, showing system precision. %RSD value re-
veals that the proposed method provides acceptable intra and
interday variations as shown in (Table 1).
3.3.2. Accuracy
The proposed method when evaluated for accuracy in terms of
percent recovery at three levels (80%, 100% and 120%),
showed percentage recovery at all three levels in the range of
98–102%, suggesting suitability of method to perform routine
drug analysis (Table 1).
3.3.3. Limit of detection (LOD) and limit of quantitation
(LOQ)
Limit of detection and Limit of quantitation of developed
method were found to be 255.86 and 775.33 ng/band respec-
tively, indicating acceptable sensitivity of the method.
Table 1 Analytical parameters using HPTLC method.
Parameter IH
Linearity range (ng/band) 1200–2800
Correlation coeﬃcient (r2) 0.9956 ± 0.0023
Slope ± SDa(Sa) 2.2502 ± 0.0957
Conﬁdence limit of slope 2.1315–2.3685
Intercept ± SDa (Sb) 2756 ± 174.4648
Conﬁdence limit of intercept 2539.8756–2972.1244
Limit of detection (ng/band) 255.86
Limit of quantitation (ng/band) 775.33
Bartlett’s testb 0.0365
Lack of ﬁtc 1.518
Precision (%RSD)d
Repeatability 0.67–1.14
Intermediate precision 1.02–1.44
Accuracy (% recovery)e 98.80–101.55
a Average of ﬁve determinations.
b Calculated value less than tabulated value, 9.488 at 95% con-
ﬁdence interval.
c Calculated F value less than tabulated value, 5.92 at 95%
conﬁdence interval.
d Average of three determinations for each concentration.
e Average of three determinations at each level.
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Deliberate change in different parameters like mobile phase
composition, saturation time, development distance, spot scan-
ning time interval, wavelength scan, time from spotting to
chromatography and mobile phase volume showed %relative
standard deviation of peak area less than 2%, indicating that
none of these variables signiﬁcantly affects the performance
of proposed method, thereby conﬁrming robustness of the
method (Table 2).
3.3.5. Speciﬁcity
The marketed formulation and degradation samples using the
developed method, showed peak at Rf value of 0.36 for IH that
was found to be at the same Rf value for IH standard by
comparison of chromatograms. The peak purity of IH in bothTable 2 Robustness study of the HPTLC method for determinatio
Parameters
1. Mobile phase compositiona
(EA:AA: 1.2:4.8)
(EA: AA: 0.8:5.2)
2. Saturation timea (20 ± 5 min)
3.Development distancea (8 ± 1 cm)
4. Spot scanning time intervalb (1, 2, 3, 4, 5, and 6 h)
5. Wavelength scanb (287 ± 2 nm)
6. Time from spotting to chromatographya (0, 20, 40 and 60 min)
7. Mobile phase volumea (12 ± 6 ml)
a Average of three determinations for concentration of 2500 ng/band.
b Average of three determinations for ﬁve different concentrations 1200marketed formulations and degradation samples when evalu-
ated by comparing the spectra at peak start, peak apex and
peak end positions of the spot, showed good correlation i.e.,
r(S, M) = 0.9999 and r(M, E) = 0.9997, indicating speciﬁcity
in the presence of excipients (Fig. 2). Similarly peak purity of
IH in degradation sample also showed good correlation i.e.,
r(S, M) = 0.9985 and r(M, E) = 0.9810, indicating speciﬁcity
in the presence of degradation product (Fig. 3).
3.4. Analysis of marketed tablet formulation
The marketed formulation IVABRAD 5 and 7.5 and IVABID
5 and 7.5 when analysed in triplicate using the developed meth-
od, showed only one peak at Rf value of 0.36 for IH in the
chromatogram of tablet sample hence indicating no interfer-
ence of the excipients present in the tablet formulation. The
content of IH found in IVABRAD 5 and 7.5 was in the range
of 99–100% and for IVABID 5 and 7.5 in the range of
98–102%, which proves applicability of the developed method
in routine analysis of pharmaceutical dosage form (Table 3).
3.5. Stock solution stability
The stability of IH in solution was evaluated by storing the
stock solution at room temperature for 24 h. An appropriate
volume of stock solution was applied at time point of 0, 1, 3,
6, 10, 24 h and development was done under optimized condi-
tion. After development, densitogram was evaluated for addi-
tional peaks (if any) but there was no indication of IH
instability in solution.
3.6. Stability indicating property
The suitability of the proposed method for estimation of IH in
the presence of its degradation product was conﬁrmed by per-
forming forced degradation study under various conditions.
The content of IH remaining in terms of % recovery was cal-
culated. IH recovery in 0.1 and 1 M hydrochloric acid was
ranging from 98% to 99.5% and 94% to 96% respectively.
Similarly drug recovery in 0.1 and 1 M sodium hydroxide
was ranging from 98% to 99% and 96% to 98% respectively.n of IH.
SD of area RSD(%) Rf value
1.53 1.51
0.36±0.01
0.35±0.01
0.21 0.21 0.35±0.01
0.36±0.01
0.36±0.01
1.41 1.43 0.36±0.01
0.36±0.01
0.36±0.01
1.13 1.09 0.37
1.83 1.84 0.37
1.49 1.53 0.36±0.01
1.71 1.75 0.36±0.01
, 1600, 2000, 2400 and 2800 ng.
Figure 2 In situ UV overlain spectra of IH standard and tablet dosage form, ( ) = Abbott 7.5 mg, ( ) = Abbott 5 mg,
( ) = IH standard, ( ) = Ind swift 5 mg, ( ) = Ind swift 7.5 mg.
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tion is slightly more pronounced than alkaline degradation.
Chromatograms of both acidic and alkaline conditions showed
additional peak of degradation product at an Rf value of 0.18
suggesting that degradant is common to both acid and base
hydrolysis (Fig. 4).
Chromatogram of IH in all other conditions like: oxidation
by hydrogen peroxide, dry heat and wet heat degradation,
accelerated temperature and humidity condition showed no
additional peak except IH at 0.36 ± 0.01, suggesting stability
of IH in different conditions for speciﬁed period of time. In
addition to this, colour of IH standard changed from white
to light brown when exposed to UV light and sunlight for
24 h but degradation was not observed indicating no chemical
changes in IH.Figure 3 In situ UV overlain spectra of IH standard and IH st
( ) = IH standard after 180 min of acid degradation.3.7. Degradation kinetic study
IH under stress conditions resulted in a gradual decomposition
at all the selected temperatures (70, 80, 90 and 100 C). Since
the degradation was performed with a large excess of solvent,
the degradation of IH followed pseudo-ﬁrst-order kinetics with
a linear relationship between log percentage of IH remaining
with respect to time showing good correlation co-efﬁcient
(Fig. 5). Pseudo ﬁrst-order is the term used when two reactants
are involved in the reaction but one of them is in such a large
excess that any change in its concentration is negligible com-
pared with the change in concentration of the other reactant
(drug). From slope of straight line obtained, ﬁrst order rate
constant (K), half-life (t1/2) and shelf life (t90) were calculated
at each temperature for acidic degradation processes.andard after acid degradation, ( ) = IH standard at 0 min,
Table 3 Analysis of IH in tablet dosage form.
Drug Brand name Amount present (mg per tablet) % Amount founda SD % RSD
Ivabradine hydrochloride Abbott 5 98.83 1.11 1.12
7.5 101.49 0.67 0.66
Ind swift 5 99.59 0.91 0.91
7.5 99.62 1.33 1.34
a Average of three determinations for each formulation.
Figure 4 3D densitogram showing (1) IH standard, (2) acid degradation, (3) base degradation (Rf; IH = 0.36, DP = 0.18).
Figure 5 Degradation kinetic study showing ﬁrst order plot at
70, 80, 90 and 100 C.
Figure 6 In situ UV overlain spectra of IH standard and IH
after acid degradation ( ) = IH standard, ( ) = Degrada-
tion product.
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was further subjected to ﬁt in Arrhenius equation:
LogK ¼ logA Ea
2:303RT
ð3Þ
where, K is the rate constant, A the frequency factor
(kcal mol1), Ea the energy of activation (cal mol
1), R the
gas constant (1.987 cal1K mol1) and T is the absolute
temperature (K).
A plot of (4 + log K) values versus the reciprocal tempera-
ture (1/T · 103), the Arrhenius plot, was found to be linear in
the selected temperature range (70–100 C). An extrapolation
of Arrhenius plot is used to calculate the degradation rate
constants of acidic degradation process (K25), activation energy(Ea), half life (t1/2) and shelf life (t90) at 25 C. The values of all
aforementioned parameters were: K25 = 3.335 · 105min1,
Ea = 14.24 kcal/mol, t1/2 = 346.32 h, t90 = 50.97 h.
Degradation kinetic study reveals that degradation of IH
was mainly due to acid hydrolysis at higher temperature and
the chromatogram shows that IH and acid degradation prod-
uct (DP) were well resolved with Rf of 0.36 ± 0.02 and
0.18 ± 0.02 respectively, indicating that DP has more polar
nature compared to IH. An in situ densitometric UV spectrum
shows that a wavelength of maximum absorption of acid
Table 4 Comparison of proposed HPTLC method with
reported HPLC methoda.
Parametersb Statistical analysis
F test (39)c
Intraday precision 1.431
Interday precision 6.225
Accuracy study 3.282
T test (2.776)c
Intraday precision 0.763
Interday precision 1.491
Accuracy study 0.779
a Ref. 9.
b Average of three determinations.
c Values in parenthesis represent corresponding tabulated values
of F and T at 95% conﬁdence interval.
240 M.H. Motisariya et al.degradation product is similar to IH indicating a similar chro-
mophoric structure (Fig. 6). FTIR spectra of degradation
product showed similar characteristic of peaks when compared
to peaks in IR spectra of IH. The peaks in IR spectra for IH
standard appeared at 1644 cm1 for C‚O, 1100, 1300 cm1
for C–O, 1439–1516 cm1 for C‚C aromatic ring, 1320 cm1
for C–N and acid degradation product also showed similar
peaks at respective positions, however, the region near
1100 cm1showed a considerable broadening and might be
due to overlapping of C–O and C–N vibrations. Mass spectra
of both, IH and acid degradation product when measured in
positive scan ion mode showed molecular ion peak at 469
and 470 respectively, indicating similar structural mass of acid
degradation product (M+ 1) and IH.
4. Conclusion
A speciﬁc, precise, accurate, rapid and economic stability-
indicating high-performance thin layer chromatographic
method for analysis of Ivabradine hydrochloride (IH) in bulk
drug and marketed formulations is developed and validated
according to ICH guidelines. It is found that, IH is unstable
in hydrolytic conditions only, whereas it is stable in all other
conditions for speciﬁed period of time. A major advantage of
developed HPTLC is that several samples can be run simul-
taneously using a small quantity of mobile phase unlike
HPLC, thus lowering the analysis time, sample clean up
and cost per analysis. Moreover, the proposed HPTLC meth-
od when compared with previously reported stability indicat-
ing HPLC method 9 for precision and accuracy study using F
test and T test revealed that calculated F and T values were
less than the tabulated values, stating no signiﬁcant difference
between two methods and good precision and accuracy of the
proposed HPTLC method (Table 4). The developed method
could effectively separate the drug from its degradation prod-
uct; hence it can be employed as a stability-indicating one,
also it is suitable for the analysis of IH in bulk and dosage
form and in quality control laboratories.5. Conﬂict of interest
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